Medicine
Methyldopa 250 mg tablet
Methyldopa 250 mg tablet is a generic prescription medicine for oral use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F). Protect from light.
Key facts
- Active ingredient (INN)
- Methyldopa
- Brand
- Sold under the generic name
- Strength
- 250 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 180 tablets, 90 tablets, 100 tablets
- Manufacturers
- Chartwell RXRising Pharma Holdings
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F). Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C02AB01 Methyldopa
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 June 1984
- Identifiers
- RxCUI 197956, 197958DailyMed set ID 9e22e1d8-04ec-4b67-92ea-b09c706f2703, e1114a58-9ab5-486e-85ed-360365b06396NDC 64980-571, 62135-321Application ANDA070076, NDA018934
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 180 tablet, film coated in 1 bottle | 62135-321-18 | Chartwell RX | 22 November 2022 |
| 90 tablet, film coated in 1 bottle | 62135-321-90 | Chartwell RX | 22 November 2022 |
| 100 tablet in 1 bottle | 64980-571-01 | Rising Pharma Holdings | 4 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 20 December 1962 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Methyldopa
Clinical summary
Methyldopa is a central alpha-2 adrenergic agonist. It is available as tablets for oral use. MedsAcross supplies Methyldopa for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MethyldopaFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Methyldopa prescribing information (Chartwell RX) · U.S. National Library of Medicine, DailyMed
Need Methyldopa 250 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.